Cerity Partners
UTHR icon

Cerity Partners’s United Therapeutics UTHR Stock Holding History

Cerity Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11M Sell
20,210
-4,158
-17% -$2.34M 0.01% 719
2026
Q1 		$14.5M Sell
24,368
-6,436
-21% -$3.21M 0.02% 544
2025
Q4 		$15M Buy
30,804
+17,657
+134% +$8.22M 0.02% 495
2025
Q3 		$5.51M Buy
13,147
+304
+2% +$102K 0.01% 813
2025
Q2 		$3.69M Buy
12,843
+5,600
+77% +$1.67M 0.01% 949
2025
Q1 		$2.23M Sell
7,243
-4,345
-37% -$1.49M ﹤0.01% 1069
2024
Q4 		$4.1M Buy
11,588
+2,702
+30% +$993K 0.01% 794
2024
Q3 		$3.18M Buy
8,886
+4,005
+82% +$1.35M 0.01% 885
2024
Q2 		$1.55M Sell
4,881
-700
-13% -$185K ﹤0.01% 1028
2024
Q1 		$1.28M Buy
5,581
+3,672
+192% +$829K ﹤0.01% 1162
2023
Q4 		$420K Buy
+1,909
New +$440K ﹤0.01% 1344
2023
Q3 		– Sell
-1,957
Closed -$432K – 1711
2023
Q2 		$432K Buy
1,957
+83
+4% +$18.4K ﹤0.01% 1246
2023
Q1 		$420K Sell
1,874
-70
-4% -$17.3K ﹤0.01% 1376
2022
Q4 		$541K Buy
+1,944
New +$491K ﹤0.01% 912
2020
Q1 		– Sell
-3,669
Closed -$323K – 522
2019
Q4 		$323K Buy
3,669
+765
+26% +$67.3K 0.02% 420
2019
Q3 		$232K Buy
2,904
+8
+0.3% +$644 0.01% 432
2019
Q2 		$226K Buy
2,896
+119
+4% +$11.1K 0.01% 436
2019
Q1 		$326K Buy
2,777
+34
+1% +$3.96K 0.02% 406
2018
Q4 		$299K Buy
2,743
+750
+38% +$87K 0.02% 406
2018
Q3 		$255K Sell
1,993
-194
-9% -$24K 0.02% 456
2018
Q2 		$247K Sell
2,187
-113
-5% -$12.4K 0.02% 469
2018
Q1 		$258K Buy
2,300
+314
+16% +$39.9K 0.02% 466
2017
Q4 		$294K Buy
1,986
+4
+0.2% +$508 0.02% 453
2017
Q3 		$232K Buy
1,982
+1
+0.1% +$128 0.02% 501
2017
Q2 		$257K Buy
1,981
+15
+0.8% +$1.87K 0.02% 307
2017
Q1 		$266K Buy
+1,966
New +$298K 0.02% 365

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JTL
Jupiter Topco LLC New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Cerity Partners's UTHR Position: Q2 2026 in Review

Cerity Partners reduced its United Therapeutics (UTHR) stake by 17% in Q2 2026, selling an estimated $2.34M and leaving 20,210 shares worth $11M. The position accounts for 0.01% of the portfolio, ranked #719.

Cerity Partners first reported a position in UTHR in Q1 2017 and has held it in 26 quarters since. The position peaked at $15M in Q4 2025. 818 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Cerity Partners held 20,210 shares of United Therapeutics worth $11M as of Q2 2026.
  • Cerity Partners sold 4,158 United Therapeutics shares in Q2 2026, an estimated $2.34M.
  • United Therapeutics made up 0.01% of Cerity Partners's portfolio in Q2 2026, its #719 holding.
  • Cerity Partners first reported a position in United Therapeutics in Q1 2017 and has held it in 26 quarters since.
  • Cerity Partners's United Therapeutics position peaked at $15M in Q4 2025.
  • 818 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.